Molecular staging individualizing cancer management

Journal of Surgical Oncology

Volumn 105, Issue 5, 2012, Pages 468-474

  Mejia, Alex ^a   Schulz, Stephanie ^a   Hyslop, Terry ^a   Weinberg, David S ^b   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

colorectal cancer; guanylyl cyclase C; GUCY2C; lymph nodes; metastatic disease; predictive markers; prognostic markers; quantitative reverse transcriptase polymerase chain reaction; staging

Indexed keywords

CYCLIC GMP; EPIDERMAL GROWTH FACTOR; GUANYLATE CYCLASE; GUANYLIN; UROGUANYLIN; VASCULOTROPIN;

ALGORITHM; CANCER CELL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; DNA DAMAGE; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GENETIC ASSOCIATION; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MOLECULAR DIAGNOSIS; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR CELL; TUMOR VOLUME;

COLONIC NEOPLASMS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, GUANYLATE CYCLASE-COUPLED; RECEPTORS, PEPTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84859091980     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21858     Document Type: Review

References (117)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66. (Pubitemid 46148091)
2. Compton CC, Greene FL,: The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004; 54: 295-308. (Pubitemid 40073988)
3. Greene FL,: AJCC cancer staging manual, 6th edition. New York: Springer; 2002.
4. Iddings D, Ahmad A, Elashoff D, et al.: The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: A meta-analysis. Ann Surg Oncol 2006; 13: 1386-1392. (Pubitemid 44749649)
5. Nicastri DG, Doucette JT, Godfrey TE, et al.: Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. J Mol Diagn 2007; 9: 563-571. (Pubitemid 350158413)
6. Meyerhardt JA, Mayer RJ,: Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-487.
7. Ries LA, Wingo PA, Miller DS, et al.: The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000; 88: 2398-2424. (Pubitemid 30247142)
8. Sobrero A, Kerr D, Glimelius B, et al.: New directions in the treatment of colorectal cancer: A look to the future. Eur J Cancer 2000; 36: 559-566. (Pubitemid 30156840)
9. Wolpin BM, Meyerhardt JA, Mamon HJ, et al.: Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007; 57: 168-185. (Pubitemid 46798625)
10. Allee PE, Tepper JE, Gunderson LL, et al.: Postoperative radiation therapy for incompletely resected colorectal carcinoma. Int J Radiat Oncol Biol Phys 1989; 17: 1171-1176. (Pubitemid 20028632)
11. Dukes CE, Bussey HJ,: The spread of rectal cancer and its effect on prognosis. Br J Cancer 1958; 12: 309-320.
12. Galandiuk S, Wieand HS, Moertel CG, et al.: Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992; 174: 27-32.
13. Minsky BD, Mies C, Rich TA, et al.: Potentially curative surgery of colon cancer: The influence of blood vessel invasion. J Clin Oncol 1988; 6: 119-127. (Pubitemid 18039999)
14. Newland RC, Chapuis PH, Pheils MT, et al.: The relationship of survival to staging and grading of colorectal carcinoma: A prospective study of 503 cases. Cancer 1981; 47: 1424-1429. (Pubitemid 11090512)
15. Olson RM, Perencevich NP, Malcolm AW, et al.: Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum. Cancer 1980; 45: 2969-2974. (Pubitemid 11191741)
16. Phillips RK, Hittinger R, Blesovsky L, et al.: Large bowel cancer: Surgical pathology and its relationship to survival. Br J Surg 1984; 71: 604-610. (Pubitemid 14098944)
17. Rubio CA, Emas S, Nylander G,: A critical reappraisal of Dukes' classification. Surg Gynecol Obstet 1977; 145: 682-684. (Pubitemid 8225363)
18. Sinicrope FA, Sugarman SM,: Role of adjuvant therapy in surgically resected colorectal carcinoma. Gastroenterology 1995; 109: 984-993.
19. Willett CG, Tepper JE, Cohen AM, et al.: Failure patterns following curative resection of colonic carcinoma. Ann Surg 1984; 200: 685-690. (Pubitemid 15216745)
20. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351. (Pubitemid 38702845)
21. Bilchik AJ, Hoon DS, Saha S, et al.: Prognostic impact of micrometastases in colon cancer: Interim results of a prospective multicenter trial. Ann Surg 2007; 246: 568-575; discussion 575-567. (Pubitemid 47480600)
22. Mamounas E, Wieand S, Wolmark N, et al.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17: 1349-1355. (Pubitemid 29220839)
23. Quasar Collaborative Group, Gray R, Barnwell J, et al.: Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 2007; 370: 2020-2029.
24. Iddings D, Bilchik A,: The biologic significance of micrometastatic disease and sentinel lymph node technology on colorectal cancer. J Surg Oncol 2007; 96: 671-677.
25. Ratto C, Sofo L, Ippoliti M, et al.: Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance. Dis Colon Rectum 1999; 42: 143-154; discussion 154-148.
26. Buie WD, Rothernberger DA,: Surveillance after curative resection o colorectal cancer: Individualing follow-up. Gastrointest Endosc Clin N Am 1993; 3: 691-713. (Pubitemid 23303434)
27. Sloane JP,: Molecules and micrometastases. Lancet 1995; 345: 1255-1256.
28. Greenson JK, Isenhart CE, Rice R, et al.: Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 1994; 73: 563-569. (Pubitemid 24046594)
29. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, et al.: Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998; 339: 223-228. (Pubitemid 28350164)
30. Andre T, Sargent D, Tabernero J, et al.: Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol 2006; 13: 887-898. (Pubitemid 43727375)
31. de Gramont A, Tournigand C, Andre T, et al.: Targeted agents for adjuvant therapy of colon cancer. Semin Oncol 2006; 33: S42-S45.
32. de Gramont A, Tournigand C, Andre T, et al.: Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol 2007; 34: S37-S40. (Pubitemid 46590359)
33. Fuchs CS, Mayer RJ,: Adjuvant chemotherapy for colon and rectal cancer. Semin Oncol 1995; 22: 472-487.
34. Krook JE, Moertel CG, Gunderson LL, et al.: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709-715.
35. Moertel CG, Fleming TR, Macdonald JS, et al.: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-358. (Pubitemid 20042739)
36. Wolmark N, Rockette H, Fisher B, et al.: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11: 1879-1887. (Pubitemid 23304611)
37. Kopetz S, Chang GJ, Overman MJ, et al.: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683.
38. Sargent D, Sobrero A, Grothey A, et al.: Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009; 27: 872-877.
39. Benson AB, III, Schrag D, Somerfield MR, et al.: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-3419. (Pubitemid 41103700)
40. Figueredo A, Charette ML, Maroun J, et al.: Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004; 22: 3395-3407. (Pubitemid 41103699)
41. Winn RJ, McClure JS,: The NCCN clinical practice guidelines in oncology: A Primer for Users. J Natl Compr Canc Netw 2003; 1: 5-13.
42. Frick GS, Pitari GM, Weinberg DS, et al.: Guanylyl cyclase C: A molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev Mol Diagn 2005; 5: 701-713. (Pubitemid 41337465)
43. Gelmann A, Desnoyers R, Cagir B, et al.: Colorectal cancer staging and adjuvant chemotherapy. Expert Opin Pharmacother 2000; 1: 737-755.
44. Waldman SA, Hyslop T, Schulz S, et al.: Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA 2009; 301: 745-752.
45. Cagir B, Gelmann A, Park J, et al.: Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann Intern Med 1999; 131: 805-812.
46. Almenoff JS, Williams SI, Scheving LA, et al.: Ligand-based histochemical localization and capture of cells expressing heat-stable enterotoxin receptors. Mol Microbiol 1993; 8: 865-873. (Pubitemid 23171468)
47. Carrithers SL, Barber MT, Biswas S, et al.: Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci USA 1996; 93: 14827-14832. (Pubitemid 26419054)
48. Carrithers SL, Parkinson SJ, Goldstein S, et al.: Escherichia coli heat-stable toxin receptors in human colonic tumors. Gastroenterology 1994; 107: 1653-1661.
49. Cohen MB, Guarino A, Shukla R, et al.: Age-related differences in receptors for Escherichia coli heat-stable enterotoxin in the small and large intestine of children. Gastroenterology 1988; 94: 367-373. (Pubitemid 18054771)
50. Cohen MB, Moyer MS, Luttrell M, et al.: The immature rat small intestine exhibits an increased sensitivity and response to Escherichia coli heat-stable enterotoxin. Pediatr Res 1986; 20: 555-560. (Pubitemid 16096757)
51. Guarino A, Cohen M, Thompson M, et al.: T84 cell receptor binding and guanyl cyclase activation by Escherichia coli heat-stable toxin. Am J Physiol 1987; 253: G775-G780.
52. Guarino A, Cohen MB, Giannella RA,: Small and large intestinal guanylate cyclase activity in children: Effect of age and stimulation by Escherichia coli heat-stable enterotoxin. Pediatr Res 1987; 21: 551-555. (Pubitemid 17076186)
53. Guarino A, Cohen MB, Overmann G, et al.: Binding of E. coli heat-stable enterotoxin to rat intestinal brush borders and to basolateral membranes. Dig Dis Sci 1987; 32: 1017-1026. (Pubitemid 17137984)
54. Lucas KA, Pitari GM, Kazerounian S, et al.: Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000; 52: 375-414.
55. Rao MC, Guandalini S, Smith PL, et al.: Mode of action of heat-stable Escherichia coli enterotoxin. Tissue and subcellular specificities and role of cyclic GMP. Biochim Biophys Acta 1980; 632: 35-46. (Pubitemid 11233185)
56. Carrithers SL, Ott CE, Hill MJ, et al.: Guanylin and uroguanylin induce natriuresis in mice lacking guanylyl cyclase-C receptor. Kidney Int 2004; 65: 40-53. (Pubitemid 38037490)
57. Field M,: Mechanisms of action of cholera and Escherichia coli enterotoxins. Am J Clin Nutr 1979; 32: 189-196.
58. Field M, Graf LH, Jr., Laird WJ, et al.: Heat-stable enterotoxin of Escherichia coli: In vitro effects on guanylate cyclase activity, cyclic GMP concentration, and ion transport in small intestine. Proc Natl Acad Sci USA 1978; 75: 2800-2804. (Pubitemid 8374996)
59. Guerrant RL, Hughes JM, Chang B, et al.: Activation of intestinal guanylate cyclase by heat-stable enterotoxin of Escherichia coli: Studies of tissue specificity, potential receptors, and intermediates. J Infect Dis 1980; 142: 220-228. (Pubitemid 10004075)
60. Hughes JM, Murad F, Chang B, et al.: Role of cyclic GMP in the action of heat-stable enterotoxin of Escherichia coli. Nature 1978; 271: 755-756. (Pubitemid 8278343)
61. Kuno T, Kamisaki Y, Waldman SA, et al.: Characterization of the receptor for heat-stable enterotoxin from Escherichia coli in rat intestine. J Biol Chem 1986; 261: 1470-1476. (Pubitemid 16144798)
62. Schulz S, Green CK, Yuen PS, et al.: Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell 1990; 63: 941-948. (Pubitemid 120034935)
63. Li P, Lin JE, Chervoneva I, et al.: Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am J Pathol 2007; 171: 1847-1858.
64. Li P, Lin JE, Snook AE, et al.: Colorectal cancer as a paracrine deficiency syndrome amenable to oral hormone replacement therapy. Clin Transl Sci 2008; 1: 163-167.
65. Li P, Lin JE, Schulz S, et al.: Can colorectal cancer be prevented or treated by oral hormone replacement therapy? Curr Mol Pharmacol 2009; 2: 285-292. PMID: 20021465
66. Li P, Schulz S, Bombonati A, et al.: Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology 2007; 133: 599-607. (Pubitemid 47187356)
67. Lin JE, Li P, Snook AE, et al.: Guanylyl cyclase C in colorectal cancer: Susceptibility gene and potential therapeutic target. Future Oncol 2009; 5: 509-522.
68. Lin JE, Li P, Snook AE, et al.: The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology 2010; 138: 241-254.
69. Pitari GM, Baksh RI, Harris DM, et al.: Interruption of homologous desensitization in cyclic guanosine 3′,5′-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins. Cancer Res 2005; 65: 11129-11135. (Pubitemid 41713384)
70. Pitari GM, Di Guglielmo MD, Park J, et al.: Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc Natl Acad Sci USA 2001; 98: 7846-7851. (Pubitemid 32642649)
71. Pitari GM, Li P, Lin JE, et al.: The paracrine hormone hypothesis of colorectal cancer. Clin Pharmacol Ther 2007; 82: 441-447. (Pubitemid 47414353)
72. Pitari GM, Lin JE, Shah FJ, et al.: Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells. Carcinogenesis 2008; 29: 1601-1607.
73. Pitari GM, Zingman LV, Hodgson DM, et al.: Bacterial enterotoxins are associated with resistance to colon cancer. Proc Natl Acad Sci USA 2003; 100: 2695-2699. (Pubitemid 36297561)
74. Shailubhai K, Yu HH, Karunanandaa K, et al.: Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res 2000; 60: 5151-5157.
75. Steinbrecher KA, Wowk SA, Rudolph JA, et al.: Targeted inactivation of the mouse guanylin gene results in altered dynamics of colonic epithelial proliferation. Am J Pathol 2002; 161: 2169-2178. (Pubitemid 35434862)
76. Birkenkamp-Demtroder K, Lotte Christensen, Harder L, et al.: Gene expression in colorectal cancer. Cancer Res 2002; 62: 4352-4363. (Pubitemid 34827293)
77. Cohen MB, Hawkins JA, Witte DP,: Guanylin mRNA expression in human intestine and colorectal adenocarcinoma. Lab Invest 1998; 78: 101-108. (Pubitemid 28074313)
78. Notterman DA, Alon U, Sierk AJ, et al.: Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 2001; 61: 3124-3130. (Pubitemid 32691964)
79. Steinbrecher KA, Tuohy TM, Heppner Goss K, et al.: Expression of guanylin is downregulated in mouse and human intestinal adenomas. Biochem Biophys Res Commun 2000; 273: 225-230. (Pubitemid 30426891)
80. Wilson C, Schulz S, Hyslop Waldman SA,: Silencing of guanylin and uroguanylin expression in colon cancer 2009; Submitted.
81. Birbe R, Palazzo JP, Walters R, et al.: Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol 2005; 36: 170-179. (Pubitemid 40313574)
82. Fava TA, Desnoyers R, Schulz S, et al.: Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood. J Clin Oncol 2001; 19: 3951-3959. (Pubitemid 32912022)
83. Waldman SA, Barber M, Pearlman J, et al.: Heterogeneity of guanylyl cyclase C expressed by human colorectal cancer cell lines in vitro. Cancer Epidemiol Biomarkers Prev 1998; 7: 505-514. (Pubitemid 28354114)
84. Waldman SA, Cagir B, Rakinic J, et al.: Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer. Dis Colon Rectum 1998; 41: 310-315. (Pubitemid 28141595)
85. Schulz S, Hyslop T, Haaf J, et al.: A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res 2006; 12: 4545-4552. (Pubitemid 44297803)
86. Witek ME, Nielsen K, Walters R, et al.: The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin Cancer Res 2005; 11: 8549-8556. (Pubitemid 43005899)
87. Chang GJ, Rodriguez-Bigas MA, Skibber JM, et al.: Lymph node evaluation and survival after curative resection of colon cancer: Systematic review. J Natl Cancer Inst 2007; 99: 433-441. (Pubitemid 47073566)
88. Govindarajan A, Baxter NN,: Lymph node evaluation in early-stage colon cancer. Clin Colorectal Cancer 2008; 7: 240-246.
89. Johnson PM, Porter GA, Ricciardi R, et al.: Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol 2006; 24: 3570-3575. (Pubitemid 46630528)
90. Le Voyer TE, Sigurdson ER, Hanlon AL, et al.: Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 2003; 21: 2912-2919. (Pubitemid 46621841)
91. Swanson RS, Compton CC, Stewart AK, et al.: The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003; 10: 65-71.
92. Tsikitis VL, Larson DL, Wolff BG, et al.: Survival in stage III colon cancer is independent of the total number of lymph nodes retrieved. J Am Coll Surg 2009; 208: 42-47.
93. Vather R, Sammour T, Kahokehr A, et al.: Lymph node evaluation and long-term survival in stage II and stage III colon cancer: A national study. Ann Surg Oncol 2009; 16: 585-593.
94. Bilimoria KY, Bentrem DJ, Nelson H, et al.: Use and outcomes of laparoscopic-assisted colectomy for cancer in the United States. Arch Surg 2008; 143: 832-839; discussion 839-840.
95. Hitchcock CL, Sampsel J, Young DC, et al.: Limitations with light microscopy in the detection of colorectal cancer cells. Dis Colon Rectum 1999; 42: 1046-1052. (Pubitemid 29383835)
96. Nolan T, Hands RE, Bustin SA,: Quantification of mRNA using real-time RT-PCR. Nat Protoc 2006; 1: 1559-1582.
97. Abati A, Liotta LA,: Looking forward in diagnostic pathology: The molecular superhighway. Cancer 1996; 78: 1-3. (Pubitemid 26189896)
98. Ball C, Sackett D, Phillips B, et al.: Levels of evidence and grades of recommendations. Last viewed August 10, 2009. Centre for Evidence-Based Medicine
99. Krishna R, Herman G, Wagner JA,: Accelerating drug development using biomarkers: A case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes. AAPS J 2008; 10: 401-409.
100. Lee JW, Devanarayan V, Barrett YC, et al.: Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006; 23: 312-328. (Pubitemid 43237862)
101. Lee JW, Weiner RS, Sailstad JM, et al.: Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: A conference report. Pharm Res 2005; 22: 499-511. (Pubitemid 40603246)
102. Wagner JA,: Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 2002; 18: 41-46. (Pubitemid 35191657)
103. Wagner JA,: Back to the future: Driving innovation in drug development. Clin Pharmacol Ther 2008; 83: 199-202.
104. Wagner JA,: Strategic approach to fit-for-purpose biomarkers in drug development. Annu Rev Pharmacol Toxicol 2008; 48: 631-651. (Pubitemid 351738166)
105. Wagner JA, Williams SA, Webster CJ,: Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007; 81: 104-107. (Pubitemid 46050874)
106. Williams SA, Slavin DE, Wagner JA, et al.: A cost-effectiveness approach to the qualification and acceptance of biomarkers. Nat Rev Drug Discov 2006; 5: 897-902. (Pubitemid 44660603)
107. Mejia A, Schulz S, Hyslop T, et al.: GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients. Expert Rev Mol Diagn 2009; 9: 777-785.
108. Croner RS, Peters A, Brueckl WM, et al.: Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma. Cancer 2005; 104: 395-404. (Pubitemid 40993269)
109. Frigola J, Song J, Stirzaker C, et al.: Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 2006; 38: 540-549.
110. Jen J, Kim H, Piantadosi S, et al.: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994; 331: 213-221. (Pubitemid 24226678)
111. Paik S, Shak S, Tang G, et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826. (Pubitemid 40051905)
112. Wang Y, Jatkoe T, Zhang Y, et al.: Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004; 22: 1564-1571. (Pubitemid 41079793)
113. Allegra CJ, Jessup JM, Somerfield MR, et al.: Americanx Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-2096.
114. Wilson C, Schulz S, Waldman S,: Cancer biomarkers: Where medicine, business, and public policy intersect. Biotechnol Healthc 2007; Feb: 1-7.
115. Wilson C, Schulz S, Waldman SA,: Biomarker development, commercialization, and regulation: Individualization of medicine lost in translation. Clin Pharmacol Ther 2007; 81: 153-155.
116. Holland C,: FDA-cleared/approved molecular diagnostic tests. Association for Molecular Pathology 9650 Rockville Pike, Suite E133B ethesda, MD 20814 (USA) 2006.
117. AHRQ: Quality, regulation and clinical utility of laboratory-developed tests. Agency for Healthcare Research and Quality Office of Communications and Knowledge Transfer540 Gaither Road, Suite 2000Rockville, MD 20850. 2010.